US drugmaker AbbVie revenue beat analysts' estimates for the fourth quarter in a row as sales of arthritis drug Humira jumped nearly 11%. 

The company, however, reported a net loss of $810m, or 51 cents per share, for the fourth quarter, mainly due to a charge related to its aborted $55 billion deal to buy UK drugmaker Shire. 

Excluding the charge and other special items, AbbVie earned 89 cents per share. Analysts on average had expected 86 cents per share. 

AbbVie's revenue rose 6.7% to $5.45 billion, above the average analyst estimate of $5.36 billion. 

Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ending in December. 

The company expects 2015 earnings of $4.25-$4.45 per share, up sharply from last year's $3.32 per share, citing demand for its all-oral Viekira Pak hepatitis C treatment and growing sales of Humira. 

Analysts expect Viekira Pak, approved by US regulators in December, to eventually command about 25% of the lucrative hepatitis C market. 

The drug competes with Gilead Sciences' Harvoni, a combination pill that has a list price of $93,400 for 12 weeks of treatment.